Burlington, United States
Cardurion Pharmaceuticals, founded in 2017, is a biotechnology and pharmaceutical company targeting advancements in cardiovascular health through innovative drug discovery. The company is renowned for its expertise in translating cardiac myocyte signaling pathways into groundbreaking therapeutics, specifically focusing on PDE9 and CaMKII inhibition.
Headquartered in the United States, with additional facilities in Shonan, Japan, Cardurion employs a strategic portfolio approach driven by in-house initiatives and a robust office of strategy. The organization boasts an adept team comprised of cardiovascular experts and industry veterans. These strengths have helped solidify foundational partnerships with major investors and strategic allies.
In a testament to its potential, Cardurion secured a $260 million Series B investment on July 16, 2024, supported by prominent investors like New Enterprise Associates, GV, Invus, Delos Capital, and others. The funding underscores confidence in the company’s pipeline growth and ongoing projects.
